KEYNOTE-A18: NCT04221945: Phase 3: Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer
First Posted 2020-01-09 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Meeting Abstract: 2025 ASCO Annual Meeting II June 04, 2025 Click here for details LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervic
Dec 15, 2024
KEYNOTE - 826: NCT03635567: Phase 3: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy First line Cervical cancer
First Posted 2018-08-17 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. June 3, 2023 2023 ASCO Annual Meeting Click here for details Peer-reviewed journal publication Pembrolizumab for Persistent, Recurrent, or Metastati
Dec 15, 2021